<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part2">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>2</PartID>
        <PartNumber>Part I</PartNumber>
        <PartSequenceNumber>2</PartSequenceNumber>
        <PartTitle>Hormone Therapy</PartTitle>
        <PartChapterCount>9</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap3" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>3</ChapterID>
          <ChapterNumber>Chapter 3</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_3</ChapterDOI>
          <ChapterSequenceNumber>3</ChapterSequenceNumber>
          <ChapterTitle Language="En">Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>41</ChapterFirstPage>
          <ChapterLastPage>51</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>2</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_3" CorrespondingAffiliationID="Aff1_3">
              <AuthorName DisplayOrder="Western">
                <GivenName>Hannelore</GivenName>
                <GivenName>V.</GivenName>
                <FamilyName>Heemers</FamilyName>
              </AuthorName>
              <Contact>
                <Email>hannelore.heemers@roswellpark.org</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Donald</GivenName>
                <GivenName>J.</GivenName>
                <FamilyName>Tindall</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_3">
              <OrgDivision>Department of Urology</OrgDivision>
              <OrgName>Roswell Park Cancer Institute</OrgName>
              <OrgAddress>
                <City>Buffalo</City>
                <State>NY</State>
                <Postcode>14263</Postcode>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_3" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">The concept that androgens exert control over the prostate and prostate disease dates back to the eighteenth century, when the first observations of seasonal variations in the size of the prostate gland were observed in animals. Since then, a direct link between testis-derived androgens and prostate growth was established, leading to the seminal study of Charles Huggins who demonstrated that surgical or medical castration is able to inhibit the growth of metastatic and advanced prostate cancer (CaP). Today, more than six decades after Huggins’ original groundbreaking report, so-called androgen deprivation therapies are still the preferred treatment option for CaP patients who do not benefit from surgery or radiation therapy. While such treatment regimes initially result in a clinical favorable response and an overall decrease in tumor burden in a majority of patients, disease regression is not complete, and androgen deprivation is therefore not curative. Recent findings of physiologically relevant tissue levels of androgens in castration-recurrent prostate cancer (CRPC) have led to a paradigm shift that CaP, which recurs following androgen deprivation therapy, is not androgen-independent and has rekindled research into alternative means of blocking androgen action as a therapeutic option during prostate cancer progression. Here, we explore the possibility of targeting coregulator proteins, which are critical determinants for androgenic responses, as an indirect means of blocking androgen action in CaP cells.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Androgen receptor</Keyword>
            <Keyword>Androgen</Keyword>
            <Keyword>Coactivator</Keyword>
            <Keyword>Corepressor</Keyword>
            <Keyword>Cell proliferation</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">The concept that androgens exert control over the prostate and prostate disease dates back to the eighteenth century, when observations of seasonal variations in the size of the prostate gland were made in animals. Since then, several reports established a direct link between testis-derived androgens and prostate growth. Investigators proposed and implemented androgen ablation strategies as a means to manage the prostate (reviewed in [<CitationRef CitationID="CR1_3">1</CitationRef>]). These efforts, combined with increased knowledge regarding endocrine physiology, and the functional relationships within the hypothalamus–pituitary–testes hormonal axis in particular, culminated in the seminal study of Charles Huggins who demonstrated that surgical or medical castration inhibits the growth of metastatic and advanced prostate cancer (CaP) [<CitationRef CitationID="CR1_3">1</CitationRef>]. Today, more than six decades after Huggins’ original groundbreaking report, androgen deprivation therapies are still the preferred treatment option for CaP patients who do not benefit from surgery or radiation therapy [<CitationRef CitationID="CR2_3">2</CitationRef>] (as addressed in more detail in <ExternalRef>
                <RefSource>Chap. 9</RefSource>
                <RefTarget Address="10.1007/978-1-60327-829-4_9" TargetType="DOI"/>
              </ExternalRef>). While such treatment regimes initially result in a clinically favorable response and an overall decrease in tumor burden in the majority of patients, disease regression is not complete. Thus, androgen deprivation is not curative, a fact that was recognized by Dr. Huggins [<CitationRef CitationID="CR1_3">1</CitationRef>]. Recent findings of physiologically relevant tissue levels of androgens in castration-recurrent prostate cancer (CRPC) [<CitationRef CitationID="CR3_3">3</CitationRef>] led to a paradigm shift that recurrent CaP following androgen deprivation therapy is not androgen-independent [<CitationRef CitationID="CR4_3">4</CitationRef>] and rekindled research into alternative means of blocking androgen action throughout prostate cancer progression. Here, we explore the possibility of targeting coregulator proteins, which are critical determinants for androgenic responses, as an indirect means of interfering with androgen action in CaP cells.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Androgens, the Androgen Receptor, and Prostate Cancer</Heading>
            <Para TextBreak="No">The discovery of the androgen receptor (AR), a nuclear receptor that mediates the cellular effects of androgens, and the subsequent identification and characterization of critical components of the AR transcriptional complex has considerably increased our understanding of the mechanism by which androgens affect target cells. Along with the continuously evolving insights into the synthesis and metabolism of androgens in CaP cells, this knowledge may provide a template needed for novel therapeutic strategies in the fight against CaP.</Para>
            <Section2 ID="Sec3">
              <Heading>Androgens: Synthesis and Metabolites</Heading>
              <Para TextBreak="No">Testosterone is synthesized by the testes and is the principal androgen in the male circulation (∼95% of circulating androgen). The remaining androgens in the bloodstream [principally dehydroepiandrosterone (DHEA), androstenediol, and androstenedione] are either produced by the adrenal cortex and converted into testosterone in peripheral tissues or [as is the case for dihydrotestosterone (DHT)] are derived from peripheral conversion from testosterone [<CitationRef CitationID="CR5_3">5</CitationRef>, <CitationRef CitationID="CR6_3">6</CitationRef>]. Synthesis of androgens is tightly regulated by the hypothalamic–pituitary–gonadal axis. Pulsatile secretion of luteinizing hormone (LH)-releasing hormone (LHRH) by the hypothalamus stimulates secretion of LH by the anterior pituitary, which in turn induces testicular Leydig cells to produce testosterone. Testosterone acts through a negative feedback loop to prevent LHRH release by the hypothalamus and to decrease the sensitivity of the pituitary to LHRH. Only 1–2% of circulating testosterone exists in an unbound, free form as the majority of testosterone in the bloodstream is bound to carrier proteins such as sex hormone-binding globulin (SHBG) and albumin [<CitationRef CitationID="CR5_3">5</CitationRef>–<CitationRef CitationID="CR8_3">8</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec4">
              <Heading>Basic Mechanism of Androgen Action</Heading>
              <Para TextBreak="No">Unbound, lipophilic testosterone diffuses into its target cell where it is rapidly and irreversibly converted into its more potent metabolite DHT by 5α-reductase (either type I or II, depending on the target tissue) [<CitationRef CitationID="CR9_3">9</CitationRef>]. Both testosterone and DHT exert their activities by binding to the AR, a 110-kDa member of the nuclear receptor superfamily of ligand-activated transcription factors. Since DHT binds the AR with higher affinity, its biological activity exceeds that of testosterone by up to ten times [<CitationRef CitationID="CR10_3">10</CitationRef>]. In addition, DHT dissociates from the AR more slowly than testosterone, and AR bound to DHT is more stable [<CitationRef CitationID="CR11_3">11</CitationRef>]. Apart from their local conversion into more active androgens, adrenal androgens can stimulate the AR by direct binding, albeit with low affinity [<CitationRef CitationID="CR12_3">12</CitationRef>]. In its basal, unliganded state, the AR is found primarily in the cytoplasmic compartment in a complex with heat shock proteins (Hsps) and immunophilin chaperones. Upon ligand binding, the composition of this Hsp complex is altered, and the AR undergoes a conformational change, which allows nuclear translocation of the AR [<CitationRef CitationID="CR13_3">13</CitationRef>]. Inside the nucleus, the activated AR binds to specific recognition sequences known as androgen response elements (AREs) in the promoter and enhancer regions of target genes. Two AR monomers in head-to-head conformations bind as homodimers to AREs [<CitationRef CitationID="CR14_3">14</CitationRef>], which are direct or indirect repeats of the core 5′-TGTTCT-3′, or more complex response elements harboring diverse arrangements of AREs [<CitationRef CitationID="CR15_3">15</CitationRef>, <CitationRef CitationID="CR16_3">16</CitationRef>]. Activated ARE-bound AR dimers can either interact directly with components of the transcription preinitiation complex or recruit other components that promote such functional interactions (Fig. <InternalRef RefID="Fig1">3.1</InternalRef>) (reviewed in [<CitationRef CitationID="CR17_3">17</CitationRef>]). Coregulators are among those critical recruits engaged by the AR to facilitate transcription of target genes. As a general definition, coregulators are proteins that are recruited by a transcription factor, which either enhance (i.e., coactivators) or reduce (i.e., corepressors) its transactivation but do not significantly alter the basal transcription rate and do not typically possess DNA-binding ability. Instead, coregulators such as those associated with the AR influence transcription by facilitating DNA occupancy, chromatin remodeling, and/or recruitment of general transcription factors associated with RNA polymerase II at the regulatory sites of target genes. Alternatively, coregulatory proteins govern transcription by assuring the competency of the AR to directly enhance gene expression. The latter can be achieved by modulation of the proper folding of the AR, ensuring its stability or correct subcellular localization [<CitationRef CitationID="CR17_3">17</CitationRef>].<Figure Category="Standard" Float="Yes" ID="Fig1">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 3.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Mechanism by which androgens regulate the expression of target genes. Upon transportation by the blood to its target tissues, unbound, lipophilic T diffuses into its target cell where it can be rapidly and irreversibly converted into a more potent metabolite DHT by 5α-reductase (5α-red). Both T and DHT bind to their cognate receptor, the androgen receptor (AR), which is stabilized by a heat shock (Hsp) complex. Androgen precursors of adrenal origin can be converted into more active androgens or weakly interact with the AR themselves. Upon ligand binding, the AR undergoes a conformational change, which allows it to dissociate from components of the Hsp complex and translocates to the cell nucleus. Inside the nucleus, the activated AR forms homodimers and binds to specific recognition sequences known as androgen response elements (AREs) in the promoter and enhancer regions of target genes. ARE-bound AR interacts with basal transcription factors and recruits coregulators to achieve AR target gene transcription, and ultimately, the appropriate biological response to the androgenic stimulus</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO1_3">
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_3_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">The different modes in which coregulators can affect AR-mediated transcription are reflected in the remarkable functional diversity observed in ∼170 AR-associated coregulators that have been identified to date. AR-associated coregulators fulfill activities that are directly related to a role in transcription. They can alleviate the constraints imposed by the chromatin structure (by chromatin remodeling and histone modifications), affect localization, stability, and/or turnover of components of the AR transcriptional complex (by ubiquitination and sumoylation), induce maturation and processing of transcripts (by roles in the spliceosome and RNA metabolism), or remove and repair obstacles and DNA lesions. Interestingly, some AR-associated coregulators possess functions that are harder to reconcile with active transcription taking place in the cell nucleus, such as endocytosis, cytoskeletal organization, protein folding, signal transduction and integration, scaffolds, and adaptors. The remarkable functional diversity displayed by AR-associated proteins and the number of cellular pathways with which they are involved offer a glimpse of the extraordinary level of complexity of protein–protein interactions involved in generating an AR-mediated transcriptional response [<CitationRef CitationID="CR17_3">17</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>The Androgen Receptor: Structure and Function</Heading>
              <Para TextBreak="No">Like other members of the nuclear receptor superfamily, the AR consists of four functional domains: an N-terminal domain (NTD), a DNA-binding domain (DBD), a hinge region, and a ligand-binding domain (LBD) [<CitationRef CitationID="CR18_3">18</CitationRef>, <CitationRef CitationID="CR19_3">19</CitationRef>]. The AR NTD contains the major transactivation function (AF) of the AR, termed AF-1. AF-1 functions in a ligand-independent manner, that, when separated from the LBD, gives rise to a constitutively active AR. The AF-1 domain undergoes induced folding when contacted by basal transcription factors, resulting in a more compact and active conformation that enables coregulator recruitment and transcription [<CitationRef CitationID="CR20_3">20</CitationRef>]. In addition, the NTD harbors a variable number of homopolymeric repeats, the most important of which is a polyglutamine repeat that ranges from 8 to 31 repeats in normal individuals, with an average length of 20. Shorter polyglutamine stretches give rise to a more transcriptionally active AR and have been suggested to be associated with a predisposition for CaP [<CitationRef CitationID="CR21_3">21</CitationRef>].</Para>
              <Para TextBreak="No">The centrally located DBD is the most conserved region within the nuclear receptor family. This region forms two zinc fingers, which determine the specificity of DNA recognition and AR dimerization. A C-terminal extension of the DBD is important for the overall three-dimensional structure of the DBD and plays a role in mediating the AR selectivity of DNA interaction [<CitationRef CitationID="CR15_3">15</CitationRef>, <CitationRef CitationID="CR22_3">22</CitationRef>].</Para>
              <Para TextBreak="No">The hinge region is involved in DNA binding as well as AR dimerization and has been suggested to attenuate transcriptional activity by the AR [<CitationRef CitationID="CR23_3">23</CitationRef>, <CitationRef CitationID="CR24_3">24</CitationRef>]. A ligand-dependent bipartite nuclear localization signal (NLS) is located in the carboxy terminal part of the DBD and the hinge region, implicating the hinge region in AR nuclear translocation [<CitationRef CitationID="CR25_3">25</CitationRef>, <CitationRef CitationID="CR26_3">26</CitationRef>].</Para>
              <Para TextBreak="No">Similar to the LBD of other nuclear receptors, the AR LBD consists of 12 discrete α-helices. The outermost α-helix (helix-12) of the unliganded receptor is positioned further away from the ligand-binding pocket. Insertion of an agonist into the ligand-binding pocket changes the conformation of the LBD in such a way that helix-12 folds back on top of the ligand-binding site, serving as a lid to retard dissociation of the captured ligand. This movement creates a shallow hydrophobic groove at the top of the ligand-binding pocket, generally referred to as AF-2. AF-2 is the major protein–protein interaction surface used by nuclear receptors to recruit LXXLL-motif containing coactivators [<CitationRef CitationID="CR27_3">27</CitationRef>]. The AR, however, differs from other nuclear receptors in this respect and interacts with coactivators in a unique manner [<CitationRef CitationID="CR28_3">28</CitationRef>]. The hydrophobic pocket within the AR LBD facilitates intramolecular and intermolecular interaction between the AR NTD and its C-terminus and is apparently not readily available for coactivator binding. It has been suggested that competition exists between these regulatory proteins and the NTD for binding to the AF-2. The implications of such competition and the association of NTD and LBD are not clear, but suggest that additional surfaces outside this well-defined coactivator pocket enable the AR to interact with its coactivators and that different classes of coactivators may interact with different AR surfaces. Experiments delineating the various domains within the AR with which coregulator proteins interact support this hypothesis (reviewed in [<CitationRef CitationID="CR17_3">17</CitationRef>]). Overall, the AF-2 in the AR LBD displays relatively weak ligand-dependent transactivating properties when compared to the AF-2 of other nuclear receptors. Nonetheless, mutation or deletion of AF-2 markedly reduces transcriptional activation in response to ligand. Noteworthy, the two major therapeutic approaches used to achieve androgen deprivation in CaP patients, i.e., surgical or medical castration, which prevent the production of ligands for the AR or administration of AR antagonists, which compete with androgenic ligands for binding to the AR, are both targeted toward the AR LBD.</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Clinical Relevance and Therapeutic Potential of the AR Signaling Axis in CaP</Heading>
              <Para TextBreak="No">The therapeutic potential of the AR signaling pathway in hormone-naïve prostate cancer has been evident since Charles Huggins’ work established castration as a systemic treatment for CaP [<CitationRef CitationID="CR1_3">1</CitationRef>, <CitationRef CitationID="CR2_3">2</CitationRef>]. Over the last decade, several lines of investigation have led to the recognition that the AR is a critical determinant for CRPC cell proliferation and therefore is an attractive target for therapeutic intervention in CRPC, despite the castrate levels of circulating androgens in these patients [<CitationRef CitationID="CR29_3">29</CitationRef>–<CitationRef CitationID="CR31_3">31</CitationRef>]. Immunohistochemical assessment of castration recurrent specimens confirmed the presence of the AR in the nucleus of CRPC cells, where it was found to be expressed at levels similar to those in androgen-stimulated CaP and benign prostate. In addition, expression profiling of CaP from castration recurrent patients has demonstrated high expression levels of genes known to be under androgen control, indicating activation of the AR transcriptional program in CRPC cells. More importantly, several preclinical studies using cultured cell and xenograft CaP models demonstrated that CRPC cells rely on the presence of a functional AR to proliferate. The “reactivation” of the AR in CRPC cells has been attributed to mechanisms of AR hypersensitivity (AR amplification and/or mutations that render the AR more sensitive to lower levels of ligands), promiscuous activation of the AR (by adrenal androgens, nonandrogenic steroids, and even antiandrogens), and outlaw AR pathways (AR activated by growth factors and cytokines, thereby bypassing the need for androgens) [<CitationRef CitationID="CR29_3">29</CitationRef>, <CitationRef CitationID="CR30_3">30</CitationRef>]. Moreover, measurements of physiologically relevant androgen concentrations and observations of overexpression of enzymes, which are able to catalyze the conversion of adrenal androgen precursors into active androgens in CRPC indicate a critical role for intracrine production of androgens in CRPC [<CitationRef CitationID="CR4_3">4</CitationRef>, <CitationRef CitationID="CR31_3">31</CitationRef>]. These findings as well as the realization that routinely used continuous androgen deprivation therapies are not effective for treating castration recurrent disease, and arguably may induce a more aggressive phenotype, have led to the concept that alternative means of targeting AR-mediated signaling should be explored for the treatment of CRPC. In this respect, therapies directed against components of the AR transcriptional complex that interfere with AR signaling make sense. A growing body of literature suggests that AR-associated coregulator proteins could serve as attractive alternative targets [<CitationRef CitationID="CR32_3">32</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Clinical Relevance and Therapeutic Potential of Coregulators in CaP</Heading>
            <Para TextBreak="No">The appreciation of coregulators as potential therapeutic targets in the treatment of CaP stems mainly from observations of deregulated coregulator expression in CaP. Immunohistochemical analysis of CaP specimens has revealed deregulated expression of more than 50 AR-associated coregulators during disease progression (Table <InternalRef RefID="Tab1">3.1</InternalRef>). In most cases, such altered coregulator expression involves increased expression of coactivators in CaP when compared to benign prostate. Using in vitro model systems for CaP, investigators have shown that increased coactivator expression contributes substantially to the mechanism of AR activation in CRPC [<CitationRef CitationID="CR32_3">32</CitationRef>]. Overexpression of most, if not all, of the coactivators in CaP is capable of inducing AR transactivation in the presence of low levels of androgens, other steroids, and even antiandrogens, irrespective of the mutational status of the AR. In addition, such overexpression has been shown to enhance the agonistic properties of antiandrogens (CBP, [<CitationRef CitationID="CR33_3">33</CitationRef>]) and to induce coregulator association with AF-2, which is not observed during normal androgen-dependent AR activation (SRC-2, [<CitationRef CitationID="CR34_3">34</CitationRef>]) resulting in increased activity through this otherwise weak activation function. These observations suggest that elevated coactivator expression in CaP could lead to a more active AR signaling pathway, and hence, a more aggressive disease. This hypothesis is consistent with data derived from clinical studies linking coregulator expression with pathological information and patient follow-up data. These studies show that deregulated coregulator expression correlates with more aggressive disease features (such as larger tumor volumes, extraprostatic disease at time of surgery, increased cell proliferation indices, etc.) and shorter disease-free survival after prostatectomy (see Table <InternalRef RefID="Tab1">3.1</InternalRef>). It is tempting to speculate that decreases in corepressor expression, such as those observed for LATS2/KPM, also result in a more active AR signaling axis in CaP. Noteworthy, expression of a small number of coactivators has been reported to be decreased, rather than increased in CaP specimens. It has been suggested that these coactivator proteins are selectively involved in the transcriptional regulation of genes involved with cell proliferation and apoptosis although definite proof for this hypothesis is pending.<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 3.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>AR-associated coregulators that are aberrantly expressed in CaP</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="6">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <colspec colname="c6" colnum="6"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Coregulator</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA/coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Function</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>CaP expr/loc</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Aggressive disease</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>References</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>α-actinin-4</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA/coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>cytoskel</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>−</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR57_3">57</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>ARA55</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Stromal</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR58_3">58</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>ARA70</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Diverse</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR46_3">46</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>ART-27</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Diverse</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>−</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR59_3">59</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>BAF57</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>chrom remod</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR47_3">47</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>BAF155</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>chrom remod</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR60_3">60</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Bag-1L</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>(co)chap</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR61_3">61</CitationRef>, <CitationRef CitationID="CR62_3">62</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>BRG1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>chrom remod</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR63_3">63</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>β-catenin</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+ (N,C)</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR64_3">64</CitationRef>, <CitationRef CitationID="CR65_3">65</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>CARM1/PRMT5</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HMT</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR66_3">66</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Caveolin-1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Endocytosis</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR67_3">67</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>CBP</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HAT</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR33_3">33</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>cdc25B</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Cell cycle</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR68_3">68</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Cdc37</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>(co)chap</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR69_3">69</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>cyclin D1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Cell cycle</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR70_3">70</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>DJ-1/PARK7</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Diverse</SimplePara>
                      </entry>
                      <entry colname="c4"/>
                      <entry colname="c5">
                        <SimplePara>CR development</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR71_3">71</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>L-dopa-decarboxylase</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Diverse</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>NE</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR72_3">72</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>E6-AP</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>ub/prot</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>−</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR73_3">73</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>FHL2</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+ (C–N)</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR74_3">74</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>GAK/auxillin2</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Endocytosis</SimplePara>
                      </entry>
                      <entry colname="c4"/>
                      <entry colname="c5">
                        <SimplePara>CR development</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR75_3">75</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>gelsolin</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>cytoskel</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>−</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR76_3">76</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Hey1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>N–C</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR36_3">36</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>HIP1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Endocytosis</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR77_3">77</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Hsp90</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>(co)chap</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR78_3">78</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>JARID1B</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HMT</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR79_3">79</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>LATS2/KPM</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Diverse</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>−</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR80_3">80</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>LSD1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HMT</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR74_3">74</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>MED1/TRAP220</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Diverse</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR81_3">81</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>p44/MEP50</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>RNA met</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+ (N–C)</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR82_3">82</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>p300</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HAT</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR55_3">55</CitationRef>, <CitationRef CitationID="CR56_3">56</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>PAK6</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR83_3">83</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>par-4</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Apoptosis</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR84_3">84</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>PELP1/MNAR</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR85_3">85</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>PIAS3</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA/coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Sumoylation</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR86_3">86</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>PIRH2</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>ub/prot</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR87_3">87</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>PRK1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR88_3">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Rad9</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>DNA repair</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR89_3">89</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Sam68</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>RNA met</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR90_3">90</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>SENP1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Sumoylation</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR37_3">37</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>α-SGT</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>(co)chap</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+(primary), −(met)</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR91_3">91</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>SIRT1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HAT</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR92_3">92</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Smad3</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA/coR</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR93_3">93</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>SRC-1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HAT</SimplePara>
                      </entry>
                      <entry colname="c4"/>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR34_3">34</CitationRef>, <CitationRef CitationID="CR94_3">94</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>SRC-2</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HAT*</SimplePara>
                      </entry>
                      <entry colname="c4"/>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR34_3">34</CitationRef>, <CitationRef CitationID="CR40_3">40</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>SRC-3</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HAT</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR95_3">95</CitationRef>, <CitationRef CitationID="CR96_3">96</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>STAT3</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR97_3">97</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Tip30</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Diverse</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR98_3">98</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Tip60</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>HAT</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>C–N</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>yes</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR35_3">35</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>TRIM68</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>ub/prot</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR99_3">99</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>vav3</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>coA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>int/transd</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>+</SimplePara>
                      </entry>
                      <entry colname="c5"/>
                      <entry colname="c6">
                        <SimplePara>[<CitationRef CitationID="CR100_3">100</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>* Belongs to family of HAT proteins although significant HAT activity has not been demonstrated <Emphasis Type="Italic">coA</Emphasis> coactivator, <Emphasis Type="Italic">coR</Emphasis> corepressor, <Emphasis Type="Italic">cytoskel</Emphasis> cytoskeleton, <Emphasis Type="Italic">int/transd</Emphasis> signal integrator or transducer, <Emphasis Type="Italic">chrom remod</Emphasis> chromatin remodeling, <Emphasis Type="Italic">(co)chap</Emphasis> (co)chaperone, <Emphasis Type="Italic">HMT</Emphasis> histone methyl transferase, <Emphasis Type="Italic">ub/prot</Emphasis> ubiquitination/proteasome, <Emphasis Type="Italic">RNA met</Emphasis> RNA metabolism, <Emphasis Type="Italic">HAT</Emphasis> histone acetyl transferase, − decreased expression, + overexpression, <Emphasis Type="Italic">N</Emphasis> nuclear, <Emphasis Type="Italic">C</Emphasis> cytoplasmic, <Emphasis Type="Italic">N–C</Emphasis> from nucleus to cytoplasm, <Emphasis Type="Italic">C–N</Emphasis> from cytoplasm to nucleus, <Emphasis Type="Italic">NE</Emphasis> neuroendocrine phenotype, <Emphasis Type="Italic">CR</Emphasis> castration recurrence, <Emphasis Type="Italic">met</Emphasis> metastatic CaP, <Emphasis Type="Italic">CaP expr/loc</Emphasis> coregulator expression or localization pattern in CaP, <Emphasis Type="Italic">aggressive disease</Emphasis> correlation of coregulator expression with aggressive disease</SimplePara>
                </tfooter>
              </Table>
            </Para>
            <Para TextBreak="No">Alterations in coregulator expression during progression of CaP are not only limited to changes in expression levels but also can involve shifts in their subcellular distribution patterns, for example, the evolution in expression patterns of the corepressor Hey1 and the coactivator Tip60 during the progression of CaP. The immunohistochemical staining profile of Tip60 in androgen-dependent CaP varies widely, ranging from high expression in both cellular compartments to a complete lack of expression. In some specimens, solely nuclear or cytoplasmic Tip60 staining is also observed. In contrast, Tip60 is expressed almost exclusively in the nucleus in CRPC samples [<CitationRef CitationID="CR35_3">35</CitationRef>]. Hey1, on the other hand, colocalizes with AR in the epithelia of patients with benign prostatic hyperplasia, where it is found in both the cytoplasm and the nucleus. In CaP, however, a shift in Hey1 expression is observed, where Hey1 is excluded from the nucleus [<CitationRef CitationID="CR36_3">36</CitationRef>]. Thus, alterations in the subcellular localization of coregulators may affect their ability to interact with the AR and components of the AR transcriptional complex, and consequently their capacity to modulate AR-driven transcription. It should be noted that the coactivators described here not only interact exclusively with the AR but also influence transcription mediated by numerous other nuclear receptors and transcription factors. Thus, overexpression of these coregulatory proteins in CaP may also affect expression of genes by signaling mechanisms that do not necessarily involve the AR. Conversely, some level of intrinsic, nuclear receptor-independent activity by individual coactivators cannot be excluded at this time.</Para>
          </Section1>
          <Section1 ID="Sec8">
            <Heading>Potential Approaches to Target Coregulators in CaP</Heading>
            <Section2 ID="Sec9">
              <Heading>Targeting Coregulator Expression</Heading>
              <Para TextBreak="No">Given the clinical relevance and the therapeutic potential of coregulators in CaP, a better understanding of the factors or circumstances that underlie the increase in expression of these critical cofactors in CaP disease progression and/or the signaling events that affect their activity could lead to novel approaches for treating this devastating disease. To our knowledge, no evidence of amplification of coregulator genes in CaP has been reported. Instead, a growing body of evidence suggests that circumstances such as changes in the local CaP cell milieu, even treatment-induced changes, could affect coregulator expression levels [<CitationRef CitationID="CR37_3">37</CitationRef>–<CitationRef CitationID="CR42_3">42</CitationRef>]. Insights into the signals and signaling pathways that mediate these effects could lead to valid methods for targeting coregulator gene expression. In view of the importance of androgens in the natural history of CaP and their central role in the approaches for therapeutic intervention in this disease, the impact of androgen signaling on coregulator gene expression is increasingly being investigated. Thus far, changes in androgen levels have been shown to either positively or negatively affect the expression of a few coregulators (SENP1 [<CitationRef CitationID="CR37_3">37</CitationRef>], NRIP1 [<CitationRef CitationID="CR38_3">38</CitationRef>], FHL2 [<CitationRef CitationID="CR39_3">39</CitationRef>], SRC-2 [<CitationRef CitationID="CR40_3">40</CitationRef>], p300 [<CitationRef CitationID="CR41_3">41</CitationRef>], and CBP [<CitationRef CitationID="CR42_3">42</CitationRef>], respectively). Interestingly, molecular dissection of the mechanisms by which changes in the androgenic milieu alter coregulator expression indicates that at least three coactivator genes (SRC-2, SENP1, and NRIP1) are direct targets for androgen action [<CitationRef CitationID="CR37_3">37</CitationRef>, <CitationRef CitationID="CR38_3">38</CitationRef>, <CitationRef CitationID="CR40_3">40</CitationRef>] as their androgen dependency is mediated through interaction of the AR with AREs within the regulatory regions of these genes. Thus, identifying mechanisms by which androgens control coregulator gene expression that involve the activity of secondary, intermediary factors might provide therapeutical potential. Recently, our laboratory identified NF-kappaB and serum response factor (SRF) as critical determinants for androgen-induced downregulation and upregulation, respectively, of the expression of the coactivator genes p300 and FHL2 [<CitationRef CitationID="CR39_3">39</CitationRef>, <CitationRef CitationID="CR41_3">41</CitationRef>]. Importantly, NF-kappaB has been implicated in ligand-independent AR signaling in CaP cells and has been reported to bind DNA more readily in CRPC xenografts than in androgen-dependent xenografts [<CitationRef CitationID="CR43_3">43</CitationRef>–<CitationRef CitationID="CR45_3">45</CitationRef>]. In addition, we have shown that SRF activity is crucial for the proliferation of both androgen-stimulated and CRPC cells [<CitationRef CitationID="CR39_3">39</CitationRef>]. Further work is needed to fully understand the molecular machinery that coordinates androgen signaling with activity of NF-kappaB and SRF. Such studies may provide a foundation for targeting coregulator expression in treating this disease.</Para>
            </Section2>
            <Section2 ID="Sec10">
              <Heading>Targeting Coregulator Activity</Heading>
              <Para TextBreak="No">Apart from strategies directed against coregulator expression, efforts to prevent the interaction of the coregulator complex with the AR could provide an effective means of targeting coregulators of AR in CaP. In this respect, an approach aimed at disrupting the molecular interaction between the AR and its coregulators or at disturbing coregulator–coregulator interaction, or a combination of both, might be appropriate. At least under in vitro experimental conditions, such strategies using fragments derived from ARA70 and BAF57 show promise. Indeed, an ARA70 fragment, harboring its AR interacting motif, has been shown to prevent AR N/C termini interaction, as well as recruitment of SRC-2 coactivator to the AR and AR transactivation [<CitationRef CitationID="CR46_3">46</CitationRef>]. Similarly, an inhibitor derived from BAF57, termed BAF57 inhibitory peptide (BIPep), which blocks AR residence on chromatin and resultant AR-dependent gene activation, was sufficient to inhibit androgen-dependent CaP cell proliferation [<CitationRef CitationID="CR47_3">47</CitationRef>]. In order to be successfully translated into the clinic, drug design using AR-coregulator interaction sites as a template for the generation of small peptides that interfere with and compete for coregulator binding would necessarily depend on a detailed understanding of the interaction of individual coactivators with the AR and with each other.</Para>
              <Para TextBreak="No">Functionally disrupting the AR-coregulator complex may not depend on a mechanical interference as discussed above. A growing body of evidence suggests that coregulators are subject to posttranslational modifications, which determine their ability to interact with the AR and fulfill their role as regulators of AR-mediated transactivation. Strikingly, several of these modifications are executed by signaling pathways and cascades that are overly active in CaP. Such modifications are under investigating for therapeutic intervention in CaP. For instance, serum levels of some growth factors such as epidermal growth factor (EGF) and cytokines such as interleukin 6 (IL-6) are elevated in patients with CRPC [<CitationRef CitationID="CR48_3">48</CitationRef>]. Stimulation of CaP cells with EGF leads to phosphorylation of the AR-associated coactivators SRC-2 [<CitationRef CitationID="CR49_3">49</CitationRef>] and MAGEA11 [<CitationRef CitationID="CR50_3">50</CitationRef>]. Moreover, EGF stimulation also results in ubiquitination of MAGEA11 [<CitationRef CitationID="CR50_3">50</CitationRef>]. In addition, IL-6 treatment induces phosphorylation of SRC-1 [<CitationRef CitationID="CR51_3">51</CitationRef>]. These modifications result in stronger AR-coregulator interaction and increased AR-mediated transcription. The effects of EGF and IL-6 stimulation on coregulator modification are mediated by the MAPK kinase signaling cascade [<CitationRef CitationID="CR49_3">49</CitationRef>, <CitationRef CitationID="CR51_3">51</CitationRef>], the activity of which is known to be increased during CaP progression [<CitationRef CitationID="CR48_3">48</CitationRef>]. MAPK activity has also been shown to lead to phosphorylation of MED1, which in turn stimulates the intrinsic coactivation properties of MED1 [<CitationRef CitationID="CR52_3">52</CitationRef>]. Another example of the impact of cytokine-induced signaling cascades on the composition and activity of the AR transcriptional complex is illustrated by the effects of macrophage-derived cytokine IL-1beta on CaP cells. In CaP cells treated with AR antagonists, IL-1beta leads to activation of MEKK1, MEKK1-mediated removal of the coregulator TAB2 from a corepressor complex interacting with the AR NTD, and subsequent recruitment of coactivator proteins to the AR. In this case, cytokine-mediated activation of MEKK1 turns an AR antagonist into a potent agonist [<CitationRef CitationID="CR53_3">53</CitationRef>]. Apart from regulating the composition of the AR-associated coregulator complex, clinically relevant signaling pathways can affect the intrinsic enzymatic moieties of coactivators. For instance, Src and PKCδ signal transduction regulate the histone acetyl transferase (HAT) activity of p300 [<CitationRef CitationID="CR54_3">54</CitationRef>], a coactivator we have shown to be critical for CaP proliferation and to correlate with aggressive disease [<CitationRef CitationID="CR55_3">55</CitationRef>, <CitationRef CitationID="CR56_3">56</CitationRef>]. Several coregulators possess enzymatic activities that introduce posttranslational modifications in the AR and govern its transcriptional activity. Inhibition of these signaling cascades could therefore represent an attractive therapeutic option to silence AR-mediated transcription in CaP cells.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec11">
            <Heading>Conclusions and Future Perspectives</Heading>
            <Para TextBreak="No">The AR is currently under intense investigation as a target for novel therapeutic strategies for the treatment of CaP. Apart from strategies aimed at targeting the expression, stability, or degradation of the AR itself, the data presented in the chapter suggest that targeting AR transcriptional complex may hold promise for therapeutic strategy. A thorough understanding of the mechanisms and signaling events that control the expression, subcellular localization, and interaction of coregulators will be essential to reach the goal of novel coregulator-targeted therapies for CaP.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_3.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_3">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Denmeade</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">A history of prostate cancer treatment</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>389</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>12044015</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrc801</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xkt1eltbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2:389–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_3">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Miyamoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Messing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Androgen deprivation therapy for prostate cancer: current status and future prospects</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>61</VolumeID>
                <FirstPage>332</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>15389811</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20115</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtFWqtr%2FP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_3">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OH</Initials>
                  <FamilyName>Ford</FamilyName>
                  <Suffix>3rd</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Weaver</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Petrusz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">The androgen axis in recurrent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>440</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>14760063</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-1146-03</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXovVGktA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_3">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Castration-recurrent prostate cancer is not androgen-independent</ArticleTitle>
                <JournalTitle>Adv Exp Med Biol</JournalTitle>
                <VolumeID>617</VolumeID>
                <FirstPage>223</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>18497046</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/978-0-387-69080-3_21</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mohler JL. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008;617:223–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_3">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Davison</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bell</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Androgen physiology</ArticleTitle>
                <JournalTitle>Semin Reprod Med</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>71</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>16633980</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1055/s-2006-939565</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XltVGrsrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Davison SL, Bell R. Androgen physiology. Semin Reprod Med 2006;24:71–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_3">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Rainey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BR</Initials>
                  <FamilyName>Carr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sasano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Mason</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Dissecting human adrenal androgen production</ArticleTitle>
                <JournalTitle>Trends Endocrinol Metab</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>234</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12128283</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1043-2760(02)00609-4</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsVOksbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rainey WE, Carr BR, Sasano H, Suzuki T, Mason JI. Dissecting human adrenal androgen production. Trends Endocrinol Metab 2002;13:234–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_3">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Vermeulen</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Reflections concerning biochemical parameters of androgenicity</ArticleTitle>
                <JournalTitle>Aging Male</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>280</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15799123</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1080/13685530400016615</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXht1KisLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vermeulen A. Reflections concerning biochemical parameters of androgenicity. Aging Male 2004;7:280–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_3">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Pardridge</FamilyName>
                </BibAuthorName>
                <Year>1986</Year>
                <ArticleTitle Language="En">Serum bioavailability of sex steroid hormones</ArticleTitle>
                <JournalTitle>Clin Endocrinol Metab</JournalTitle>
                <VolumeID>15</VolumeID>
                <FirstPage>259</FirstPage>
                <LastPage>78</LastPage>
                <Occurrence Type="PID">
                  <Handle>3521955</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0300-595X(86)80024-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28Xlt1Omsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pardridge WM. Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab 1986;15:259–78.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_3">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Russell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Steroid 5 alpha-reductase: two genes/two enzymes</ArticleTitle>
                <JournalTitle>Annu Rev Biochem</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>25</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>7979239</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1146/annurev.bi.63.070194.000325</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXitlCitQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_3">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Deslypere</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Young</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>McPhaul</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene</ArticleTitle>
                <JournalTitle>Mol Cell Endocrinol</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>15</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>1334007</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0303-7207(92)90004-P</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38Xmt1Kmtrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992;88:15–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_3">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <Year>1976</Year>
                <ArticleTitle Language="En">Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>251</VolumeID>
                <FirstPage>5620</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>184085</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE1cXksFahsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wilson EM, French FS. Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem 1976;251:5620–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_3">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mizokami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Koh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Fujita</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Maeda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Egawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Koshida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Honma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Keller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Namiki</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>765</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>14744796</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-03-0130</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXmsValsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64:765–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_3">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Prescott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Coetzee</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Molecular chaperones throughout the life cycle of the androgen receptor</ArticleTitle>
                <JournalTitle>Cancer Lett</JournalTitle>
                <VolumeID>231</VolumeID>
                <FirstPage>12</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16356826</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.canlet.2004.12.037</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtlaitbnF</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Prescott J, Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 2006;231:12–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_3">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PL</Initials>
                  <FamilyName>Shaffer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jivan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Dollins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Claessens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DT</Initials>
                  <FamilyName>Gewirth</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Structural basis of androgen receptor binding to selective androgen response elements</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>101</VolumeID>
                <FirstPage>4758</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>15037741</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0401123101</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjsFCjtbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A 2004;101:4758–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_3">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Verrijdt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Tanner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>U</Initials>
                  <FamilyName>Moehren</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Callewaert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Haelens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Claessens</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response</ArticleTitle>
                <JournalTitle>Biochem Soc Trans</JournalTitle>
                <VolumeID>34</VolumeID>
                <FirstPage>1089</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>17073757</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1042/BST0341089</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFKgtLbJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Verrijdt G, Tanner T, Moehren U, Callewaert L, Haelens A, Claessens F. The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response. Biochem Soc Trans 2006;34:1089–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_3">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Reid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SC</Initials>
                  <FamilyName>Hendy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Saito</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Sorensen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Two classes of androgen receptor elements mediate cooperativity through allosteric interactions</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>276</VolumeID>
                <FirstPage>2943</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>11056175</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M009170200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXhtVGjtbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Reid KJ, Hendy SC, Saito J, Sorensen P, Nelson CC. Two classes of androgen receptor elements mediate cooperativity through allosteric interactions. J Biol Chem 2001;276:2943–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_3">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HV</Initials>
                  <FamilyName>Heemers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex</ArticleTitle>
                <JournalTitle>Endocr Rev</JournalTitle>
                <VolumeID>28</VolumeID>
                <FirstPage>778</FirstPage>
                <LastPage>808</LastPage>
                <Occurrence Type="PID">
                  <Handle>17940184</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/er.2007-0019</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtVKlsrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007;28:778–808.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_3">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BW</Initials>
                  <FamilyName>O’Malley</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Molecular mechanisms of action of steroid/thyroid receptor superfamily members</ArticleTitle>
                <JournalTitle>Annu Rev Biochem</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>451</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="PID">
                  <Handle>7979245</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1146/annurev.bi.63.070194.002315</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXkslequr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tsai MJ, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_3">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>White</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Parker</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Molecular mechanisms of steroid hormone action</ArticleTitle>
                <JournalTitle>Endocr Relat Cancer</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1677/erc.0.0050001</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjs1alurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>White R, Parker MG. Molecular mechanisms of steroid hormone action. Endocr Relat Cancer 1998;5:1–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_3">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DN</Initials>
                  <FamilyName>Lavery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IJ</Initials>
                  <FamilyName>McEwan</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">The human androgen receptor AF1 transactivation domain: interactions with transcription factor IIF and molten-globule-like structural characteristics</ArticleTitle>
                <JournalTitle>Biochem Soc Trans</JournalTitle>
                <VolumeID>34</VolumeID>
                <FirstPage>1054</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17073749</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1042/BST0341054</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFKgtLnL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lavery DN, McEwan IJ. The human androgen receptor AF1 transactivation domain: interactions with transcription factor IIF and molten-globule-like structural characteristics. Biochem Soc Trans 2006;34:1054–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_3">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Stampfer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Krithivas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Dahl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Brufsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Talcott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CH</Initials>
                  <FamilyName>Hennekens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">The CAG repeat within the androgen receptor gene and its relationship to prostate cancer</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                <VolumeID>94</VolumeID>
                <FirstPage>3320</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>9096391</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.94.7.3320</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXisVKgu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_3">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Schoenmakers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Verrijdt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Peeters</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Verhoeven</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Rombauts</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Claessens</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>275</VolumeID>
                <FirstPage>12290</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10766868</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.275.16.12290</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXisl2jurw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schoenmakers E, Verrijdt G, Peeters B, Verhoeven G, Rombauts W, Claessens F. Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses. J Biol Chem 2000;275:12290–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_3">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Q</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Yong</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>276</VolumeID>
                <FirstPage>7493</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11102454</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M009916200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXislKmsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang Q, Lu J, Yong EL. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 2001;276:7493–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_3">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Haelens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Tanner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Denayer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Callewaert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Claessens</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>4514</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>17483368</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-1701</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXltVyrtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 2007;67:4514–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_3">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Jenster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trapman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AO</Initials>
                  <FamilyName>Brinkmann</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Nuclear import of the human androgen receptor</ArticleTitle>
                <JournalTitle>Biochem J</JournalTitle>
                <VolumeID>293</VolumeID>
                <FirstPage>761</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8352744</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXlsFags7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jenster G, Trapman J, Brinkmann AO. Nuclear import of the human androgen receptor. Biochem J 1993;293:761–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_3">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ZX</Initials>
                  <FamilyName>Zhou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Sar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Simental</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MV</Initials>
                  <FamilyName>Lane</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH<Subscript>2</Subscript>-terminal and carboxyl-terminal sequences</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>269</VolumeID>
                <FirstPage>13115</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>8175737</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c3jtVCjtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH<Subscript>2</Subscript>-terminal and carboxyl-terminal sequences. J Biol Chem 1994;269:13115–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_3">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Heery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Kalkhoven</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hoare</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Parker</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">A signature motif in transcriptional co-activators mediates binding to nuclear receptors</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>387</VolumeID>
                <FirstPage>733</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>9192902</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/42750</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXktVansro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997;387:733–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_3">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CY</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>McDonnell</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Androgen receptor–cofactor interactions as targets for new drug discovery</ArticleTitle>
                <JournalTitle>Trends Pharmacol Sci</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>225</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>15860367</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.tips.2005.03.002</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjslKhs7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chang CY, McDonnell DP. Androgen receptor–cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 2005;26:225–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_3">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Grossmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Androgen receptor signaling in androgen-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>93</VolumeID>
                <FirstPage>1687</FirstPage>
                <LastPage>97</LastPage>
                <Occurrence Type="PID">
                  <Handle>11717329</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/93.22.1687</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXpt1Kjtr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93:1687–97.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_3">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Debes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Mechanisms of androgen-refractory prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1488</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470210</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMp048178</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmurw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_3">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">A role for the androgen-receptor in clinically localized and advanced prostate cancer</ArticleTitle>
                <JournalTitle>Best Pract Res Clin Endocrinol Metab</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>357</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>18471792</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.beem.2008.01.009</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlslygtrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mohler JL. A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 2008;22:357–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_3">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HV</Initials>
                  <FamilyName>Heemers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Androgen receptor coregulatory proteins as potential therapeutic targets in the treatment of prostate cancer</ArticleTitle>
                <JournalTitle>Curr Cancer Ther Rev</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>175</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.2174/1573394054021745</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXltlSisLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heemers HV, Tindall DJ. Androgen receptor coregulatory proteins as potential therapeutic targets in the treatment of prostate cancer. Curr Cancer Ther Rev 2005;1:175–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_3">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Comuzzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Lambrinidis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Rogatsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Godoy-Tundidor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Knezevic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Krhen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Marekovic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bartsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Klocker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobisch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen and anti-androgen-induced androgen receptor function</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>162</VolumeID>
                <FirstPage>233</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>12507906</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0002-9440(10)63814-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlsF2jsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen and anti-androgen-induced androgen receptor function. Am J Pathol 2003;162:233–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_3">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OH</Initials>
                  <FamilyName>Ford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <FirstPage>4315</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11389051</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXktlSquro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_3">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Halkidou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VJ</Initials>
                  <FamilyName>Gnanapragasam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PB</Initials>
                  <FamilyName>Mehta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IR</Initials>
                  <FamilyName>Logan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Brady</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Cook</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HY</Initials>
                  <FamilyName>Leung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Neal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Robson</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>2466</FirstPage>
                <LastPage>77</LastPage>
                <Occurrence Type="PID">
                  <Handle>12717424</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1206342</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjt1alsL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003;22:2466–77.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_3">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Belandia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Powell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>García-Pedrero</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Walker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Bevan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Parker</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Hey1, a mediator of notch signaling, is an androgen receptor corepressor</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>1425</FirstPage>
                <LastPage>36</LastPage>
                <Occurrence Type="PID">
                  <Handle>15684393</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1128/MCB.25.4.1425-1436.2005</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhs1Kgtrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Belandia B, Powell SM, García-Pedrero JM, Walker MM, Bevan CL, Parker MG. Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol 2005;25:1425–36.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_3">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Bawa-Khalfe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Yeh</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>282</VolumeID>
                <FirstPage>37341</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>17932034</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M706978200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhsVGjtrzM</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bawa-Khalfe T, Cheng J, Wang Z, Yeh ET. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem 2007;282:37341–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_3">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PH</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YP</Initials>
                  <FamilyName>Tsao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability</ArticleTitle>
                <JournalTitle>Nucleic Acids Res</JournalTitle>
                <VolumeID>36</VolumeID>
                <FirstPage>51</FirstPage>
                <LastPage>66</LastPage>
                <Occurrence Type="PID">
                  <Handle>17984071</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/nar/gkm942</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXpt12mug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chen PH, Tsao YP, Wang CC, Chen SL. Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability. Nucleic Acids Res 2008;36:51–66.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_3">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HV</Initials>
                  <FamilyName>Heemers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Regan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Dehm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>10592</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>17975004</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-1917</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1erurvE</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heemers HV, Regan KM, Dehm SM, Tindall DJ. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res 2007;67:10592–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_3">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IU</Initials>
                  <FamilyName>Agoulnik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Vaid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Alvarado</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Bingman</FamilyName>
                  <Suffix>3rd</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Erdem</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Frolov</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GE</Initials>
                  <FamilyName>Ayala</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Ittmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Weigel</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>10594</FirstPage>
                <LastPage>602</LastPage>
                <Occurrence Type="PID">
                  <Handle>17079484</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-1023</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFGjsrfL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman 3rd WE, Erdem H, et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006;66:10594–602.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_3">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HV</Initials>
                  <FamilyName>Heemers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Sebo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Debes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Regan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Raclaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobisch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen deprivation increases p300 expression in prostate cancer cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>3422</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>17409453</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-2836</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksVGksbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 2007;67:3422–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_3">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Comuzzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Nemes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Jasarevic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Lodde</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Pycha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bartsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Offner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobisch</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer</ArticleTitle>
                <JournalTitle>J Pathol</JournalTitle>
                <VolumeID>204</VolumeID>
                <FirstPage>159</FirstPage>
                <LastPage>66</LastPage>
                <Occurrence Type="PID">
                  <Handle>15378487</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/path.1609</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXps1Kisbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, et al. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 2004;204:159–66.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_3">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Shukla</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT</Initials>
                  <FamilyName>MacLennan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Marengo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MI</Initials>
                  <FamilyName>Resnick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Gupta</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Constitutive activation of PI3K-Akt and NF-κB during prostate cancer progression in autochtonous transgenic mouse model</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>224</FirstPage>
                <LastPage>39</LastPage>
                <Occurrence Type="PID">
                  <Handle>15712212</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20217</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXotFSmt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shukla S, MacLennan GT, Marengo SR, Resnick MI, Gupta S. Constitutive activation of PI3K-Akt and NF-κB during prostate cancer progression in autochtonous transgenic mouse model. Prostate 2005;64:224–39.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_3">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SO</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Lou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Nadiminty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Gao</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>160</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>15678501</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20218</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXlvFSitbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 2005;64:160–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_3">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CD</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Sawyers</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>2862</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>11909978</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1128/MCB.22.8.2862-2870.2002</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XislWnt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22:2862–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_3">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>YC</Initials>
                  <FamilyName>Hu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yeh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Yeh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ER</Initials>
                  <FamilyName>Sampson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Hsu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HJ</Initials>
                  <FamilyName>Ting</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HK</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Ni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>279</VolumeID>
                <FirstPage>33438</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>15166229</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M401781200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXmtFOitL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, et al. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem 2004;279:33438–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_3">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Link</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Balasubramaniam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sharma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Comstock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Godoy-Tundidor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Powers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Cao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Haelens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Claessens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Revelo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KE</Initials>
                  <FamilyName>Knudsen</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>4551</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>18559499</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-6392</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnt1aqtrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Link KA, Balasubramaniam S, Sharma A, Comstock CE, Godoy-Tundidor S, Powers N, et al. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res 2008;68:4551–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_3">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Androgen receptor cross-talk with cell signalling pathways</ArticleTitle>
                <JournalTitle>Growth Factors</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>179</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>15518241</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1080/08977190412331279908</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpt1aksrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004;22:179–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_3">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Fei</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Ponguta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HM</Initials>
                  <FamilyName>Bill</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>279</VolumeID>
                <FirstPage>7119</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>14662770</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M307649200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXht1CksLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004;279:7119–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_3">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Bai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>28</VolumeID>
                <FirstPage>1947</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>18212060</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1128/MCB.01672-07</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXjtlKjurw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bai S, Wilson EM. Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol 2008;28:1947–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_3">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Ueda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NR</Initials>
                  <FamilyName>Mawji</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Bruchovsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Sadar</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>277</VolumeID>
                <FirstPage>38087</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>12163482</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M203313200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xns1Cgurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277:38087–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_3">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PK</Initials>
                  <FamilyName>Pandey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TS</Initials>
                  <FamilyName>Udayakumar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Sharma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PS</Initials>
                  <FamilyName>Shapiro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Fondell</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>10695</FirstPage>
                <LastPage>710</LastPage>
                <Occurrence Type="PID">
                  <Handle>16314496</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1128/MCB.25.24.10695-10710.2005</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtleksbfK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pandey PK, Udayakumar TS, Lin X, Sharma D, Shapiro PS, Fondell JD. Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation. Mol Cell Biol 2005;25:10695–710.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_3">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Baek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Bourk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Ohgi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Garcia-Bassets</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sanjo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Akira</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PF</Initials>
                  <FamilyName>Kotol</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CK</Initials>
                  <FamilyName>Glass</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Rosenfeld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Rose</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>124</VolumeID>
                <FirstPage>615</FirstPage>
                <LastPage>29</LastPage>
                <Occurrence Type="PID">
                  <Handle>16469706</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.cell.2005.12.032</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhslaqsL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006;124:615–29.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_3">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OB</Initials>
                  <FamilyName>Goodman</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RG</Initials>
                  <FamilyName>Pestell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PN</Initials>
                  <FamilyName>Schlegel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Nanus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Shen</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>2011</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>16434977</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1209231</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XivFOmt7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gong J, Zhu J, Goodman Jr OB, Pestell RG, Schlegel PN, Nanus DM, et al. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 2006;25:2011–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_3">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Debes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Sebo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Lohse</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Haugen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">p300 in prostate cancer proliferation and progression</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>7638</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>14633682</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXptFOlsL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_3">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Debes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Sebo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HV</Initials>
                  <FamilyName>Heemers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BR</Initials>
                  <FamilyName>Kipp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Haugen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Lohse</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">p300 modulates nuclear morphology in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>708</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15705864</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-2837</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtVWnsbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DL, Lohse CM, et al. p300 modulates nuclear morphology in prostate cancer. Cancer Res 2005;65:708–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_3">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Hara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Honda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Shitashige</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ono</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Matsuyama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Naito</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hirohashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Yamada</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells</ArticleTitle>
                <JournalTitle>Mol Cell Proteomics</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>479</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>17151021</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjsVymtbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hara T, Honda K, Shitashige M, Ono M, Matsuyama H, Naito K, et al. Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells. Mol Cell Proteomics 2007;6:479–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_3">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Heitzer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>DeFranco</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>7326</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>16849583</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-05-2379</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XmvFGkur0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heitzer MD, DeFranco DB. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res 2006;66:7326–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_3">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SS</Initials>
                  <FamilyName>Taneja</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Ha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NK</Initials>
                  <FamilyName>Swenson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IP</Initials>
                  <FamilyName>Torra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Rome</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PD</Initials>
                  <FamilyName>Walden</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HY</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Shapiro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Garabedian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SK</Initials>
                  <FamilyName>Logan</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">ART-27, an androgen receptor coactivator regulated in prostate development and cancer</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>279</VolumeID>
                <FirstPage>13944</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>14711828</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M306576200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXis1eltrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taneja SS, Ha S, Swenson NK, Torra IP, Rome S, Walden PD, et al. ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J Biol Chem 2004;279:13944–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_3">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Heebøll</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Borre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PD</Initials>
                  <FamilyName>Ottosen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Andersen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Mansilla</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Dyrskjøt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TF</Initials>
                  <FamilyName>Orntoft</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Tørring</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation</ArticleTitle>
                <JournalTitle>Histol Histopathol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>1069</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="PID">
                  <Handle>18581278</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heebøll S, Borre M, Ottosen PD, Andersen CL, Mansilla F, Dyrskjøt L, et al. SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol 2008;23:1069–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_3">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Krajewska</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BC</Initials>
                  <FamilyName>Turner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Shabaik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Krajewski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Reed</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>801</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>16482527</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20384</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XlsFGmurg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Krajewska M, Turner BC, Shabaik A, Krajewski S, Reed JC. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers. Prostate 2006;66:801–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_3">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HE</Initials>
                  <FamilyName>Mäki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OR</Initials>
                  <FamilyName>Saramäki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Shatkina</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Martikainen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TL</Initials>
                  <FamilyName>Tammela</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Weerden</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Cato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Visakorpi</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Pathol</JournalTitle>
                <VolumeID>212</VolumeID>
                <FirstPage>395</FirstPage>
                <LastPage>401</LastPage>
                <Occurrence Type="PID">
                  <Handle>17503439</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/path.2186</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mäki HE, Saramäki OR, Shatkina L, Martikainen PM, Tammela TL, van Weerden WM, et al. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer. J Pathol 2007;212:395–401.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_3">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Tawfik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Gayed</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Thrasher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hoestje</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>203</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>17075831</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20521</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXitlWqurc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sun A, Tawfik O, Gayed B, Thrasher JB, Hoestje S, Li C, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 2007;67:203–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_3">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Shukeir</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Potti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Sircar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Aprikian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Goltzman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Rabbani</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>101</VolumeID>
                <FirstPage>1345</FirstPage>
                <LastPage>56</LastPage>
                <Occurrence Type="PID">
                  <Handle>15316903</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.20518</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXotFWnsLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 2004;101:1345–56.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_3">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HC</Initials>
                  <FamilyName>Whitaker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Girling</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AY</Initials>
                  <FamilyName>Warren</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Leung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IG</Initials>
                  <FamilyName>Mills</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Neal</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Alterations in beta-catenin expression and localization in prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>1196</FirstPage>
                <LastPage>205</LastPage>
                <Occurrence Type="PID">
                  <Handle>18459111</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20780</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtVSktrjO</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. Alterations in beta-catenin expression and localization in prostate cancer. Prostate 2008;68:1196–205.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_3">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Hong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Kao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Jeng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JN</Initials>
                  <FamilyName>Eble</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MO</Initials>
                  <FamilyName>Koch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Gardner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CX</Initials>
                  <FamilyName>Pan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Hu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT</Initials>
                  <FamilyName>MacLennan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>101</VolumeID>
                <FirstPage>83</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15221992</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.20327</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlvFCnu7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, et al. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 2004;101:83–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_3">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Karam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Lotan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CG</Initials>
                  <FamilyName>Roehrborn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Ashfaq</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PI</Initials>
                  <FamilyName>Karakiewicz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SF</Initials>
                  <FamilyName>Shariat</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>614</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>17299799</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20557</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 2007;67:614–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_3">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Ngan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Hashimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZQ</Initials>
                  <FamilyName>Ma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>734</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12569365</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1206121</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXoslOltg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003;22:734–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_3">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Stepanova</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>DeMayo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Wheeler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Finegold</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Harper</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>2186</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>10822368</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1203561</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjslelsbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC, et al. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 2000;19:2186–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_3">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Drobnjak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Osman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Fazzari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Cordon-Cardo</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>1891</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>10815912</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXktVWisLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000;6:1891–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_3">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Tillman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Yuan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Gu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Fazli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Ghosh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Flynt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gleave</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PS</Initials>
                  <FamilyName>Rennie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kasper</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>4630</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17510388</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-4556</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXltl2hu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, et al. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res 2007;67:4630–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_3">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Wafa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Palmer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Fazli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hurtado-Coll</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Bell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Gleave</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Cox</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PS</Initials>
                  <FamilyName>Rennie</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Comprehensive expression analysis of<Emphasis Type="SmallCaps">l</Emphasis>-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors</ArticleTitle>
                <JournalTitle>Hum Pathol</JournalTitle>
                <VolumeID>38</VolumeID>
                <FirstPage>161</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>16997353</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.humpath.2006.07.003</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtleisrfI</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, et al. Comprehensive expression analysis of<Emphasis Type="SmallCaps">l</Emphasis>-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 2007;38:161–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_3">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Gao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SK</Initials>
                  <FamilyName>Mohsin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Gatalica</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Fu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Sharma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Nawaz</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Decreased expression of e6-associated protein in breast and prostate carcinomas</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>146</VolumeID>
                <FirstPage>1707</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15691896</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/en.2004-1198</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXis1yqt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gao X, Mohsin SK, Gatalica Z, Fu G, Sharma P, Nawaz Z. Decreased expression of e6-associated protein in breast and prostate carcinomas. Endocrinology 2005;146:1707–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_3">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Kahl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Gullotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Heukamp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Wolf</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Friedrichs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Vorreuther</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Solleder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Bastian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Ellinger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Metzger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Schüle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Buettner</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>11341</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17145880</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-1570</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xht1KnsLzL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006;66:11341–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_3">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Ray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Wafa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Snoek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Fazli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gleave</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PS</Initials>
                  <FamilyName>Rennie</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>118</VolumeID>
                <FirstPage>1108</FirstPage>
                <LastPage>19</LastPage>
                <Occurrence Type="PID">
                  <Handle>16161052</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.21469</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhsFeksLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, et al. Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int J Cancer 2006;118:1108–19.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_3">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HK</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Driscoll</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Asch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Asch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>40</VolumeID>
                <FirstPage>14</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10344719</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0045(19990615)40:1&lt;14::AID-PROS2&gt;3.0.CO;2-6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M3nsVGitA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999;40:14–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_3">
              <CitationNumber>77</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Rao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TS</Initials>
                  <FamilyName>Hyun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PD</Initials>
                  <FamilyName>Kumar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Mizukami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Rubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Lucas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Sanda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TS</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>110</VolumeID>
                <FirstPage>351</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>12163454</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlvFKhtLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rao DS, Hyun TS, Kumar PD, Mizukami IF, Rubin MA, Lucas PC, et al. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 2002;110:351–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_3">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Cardillo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Ippoliti</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>3409</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>17094460</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xht1ersLzJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006;26:3409–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_3">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Xiang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Han</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Ye</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Peng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Ma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AP</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CD</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>104</VolumeID>
                <FirstPage>19226</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>18048344</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0700735104</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXisVKrtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A 2007;104:19226–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_3">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Powzaniuk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>McElwee-Witmer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Vogel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Hayami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Rutledge</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Harada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Rodan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LP</Initials>
                  <FamilyName>Freedman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Bai</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>18</VolumeID>
                <FirstPage>2011</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>15131260</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.2004-0065</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXmtlKqsro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, et al. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol 2004;18:2011–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_3">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Vijayvargia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>May</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Fondell</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>4034</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>17483314</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-3039</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXltVyku7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vijayvargia R, May MS, Fondell JD. A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression. Cancer Res 2007;67:4034–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_3">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Peng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Melamed</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Chiriboga</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Wei</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Kong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CX</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Feng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Garabedian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RG</Initials>
                  <FamilyName>Roeder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>105</VolumeID>
                <FirstPage>5236</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>18356297</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0712262105</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXksVKqtLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Peng Y, Chen F, Melamed J, Chiriboga L, Wei J, Kong X, et al. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A 2008;105:5236–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_3">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kaur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Yuan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Balk</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>68</VolumeID>
                <IssueID>14</IssueID>
                <FirstPage>1510</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>18642328</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20787</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXht1GqsbzL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kaur R, Yuan X, Lu ML, Balk SP. Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. Prostate 2008;68(14):1510–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_3">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Black</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Mize</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Karlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Greenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Hawley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LD</Initials>
                  <FamilyName>True</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TK</Initials>
                  <FamilyName>Takayama</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>743</FirstPage>
                <LastPage>56</LastPage>
                <Occurrence Type="PID">
                  <Handle>17373694</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20503</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmtV2rtr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Black PC, Mize GJ, Karlin P, Greenberg DL, Hawley SJ, True LD, et al. Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate 2007;67:743–56.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_3">
              <CitationNumber>85</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SS</Initials>
                  <FamilyName>Nair</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Guo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Mueller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Koochekpour</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Qiu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RR</Initials>
                  <FamilyName>Tekmal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Schüle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HJ</Initials>
                  <FamilyName>Kung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kumar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Vadlamudi</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>613</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>17192406</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.2006-0269</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXivVOrtro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nair SS, Guo Z, Mueller JM, Koochekpour S, Qiu Y, Tekmal RR, et al. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol 2007;21:613–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_3">
              <CitationNumber>86</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Banerjee</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Differential PIAS3 expression in human malignancy</ArticleTitle>
                <JournalTitle>Oncol Rep</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>1319</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>15138572</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkvVWht7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep 2004;11:1319–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_3">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IR</Initials>
                  <FamilyName>Logan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Gaughan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>McCracken</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Sapountzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HY</Initials>
                  <FamilyName>Leung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Robson</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>6502</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>16914734</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1128/MCB.00147-06</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XovFyhu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Logan IR, Gaughan L, McCracken SR, Sapountzi V, Leung HY, Robson CN. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol 2006;26:6502–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_3">
              <CitationNumber>88</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Metzger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Yin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Wissmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Kunowska</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Fischer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Friedrichs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Patnaik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Higgins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Potier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Scheidtmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Buettner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Schüle</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation</ArticleTitle>
                <JournalTitle>Nat Cell Biol</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>53</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>18066052</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ncb1668</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXkvVej</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Metzger E, Yin N, Wissmann M, Kunowska N, Fischer K, Friedrichs N, et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol 2008;10:53–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_3">
              <CitationNumber>89</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CX</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HB</Initials>
                  <FamilyName>Lieberman</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Rad9 has a functional role in human prostate carcinogenesis</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>1267</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>18316588</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-2304</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXislagtb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhu A, Zhang CX, Lieberman HB. Rad9 has a functional role in human prostate carcinogenesis. Cancer Res 2008;68:1267–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_3">
              <CitationNumber>90</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Rajan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Gaughan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Dalgliesh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>El-Sherif</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Robson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HY</Initials>
                  <FamilyName>Leung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Elliott</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor</ArticleTitle>
                <JournalTitle>J Pathol</JournalTitle>
                <VolumeID>215</VolumeID>
                <FirstPage>67</FirstPage>
                <LastPage>77</LastPage>
                <Occurrence Type="PID">
                  <Handle>18273831</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/path.2324</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmtFKrsro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, et al. The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Pathol 2008;215:67–77.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_3">
              <CitationNumber>91</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Buchanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ricciardelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Harris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Prescott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZC</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Jia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Butler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VR</Initials>
                  <FamilyName>Marshall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Gerald</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Coetzee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Tilley</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>10087</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>17942943</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-1646</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtFOnsLjL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Buchanan G, Ricciardelli C, Harris JM, Prescott J, Yu ZC, Jia L, et al. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res 2007;67:10087–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_3">
              <CitationNumber>92</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Huffman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Grizzle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Bamman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IA</Initials>
                  <FamilyName>Eltoum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Elgavish</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TR</Initials>
                  <FamilyName>Nagy</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">SIRT1 is significantly elevated in mouse and human prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>6612</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17638871</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-0085</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXnslOjt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007;67:6612–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_3">
              <CitationNumber>93</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Revelo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Dong</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>5692</FirstPage>
                <LastPage>702</LastPage>
                <Occurrence Type="PID">
                  <Handle>17908958</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-1078</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtFSntL3M</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lu S, Lee J, Revelo M, Wang X, Lu S, Dong Z. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res 2007;13:5692–702.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_3">
              <CitationNumber>94</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IU</Initials>
                  <FamilyName>Agoulnik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Vaid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Bingman</FamilyName>
                  <Suffix>3rd</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Erdeme</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Frolov</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Ayala</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Ittmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Weigel</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>7959</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>16140968</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXpslahs78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Agoulnik IU, Vaid A, Bingman 3rd WE, Erdeme H, Frolov A, Smith CL, et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005;65:7959–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_3">
              <CitationNumber>95</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HJ</Initials>
                  <FamilyName>Zhou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Yan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Luo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Ayala</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Erdem</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ittmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">SRC-3 is required for prostate cancer cell proliferation and survival</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>7976</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>16140970</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXpslahs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005;65:7976–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_3">
              <CitationNumber>96</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VJ</Initials>
                  <FamilyName>Gnanapragasam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HY</Initials>
                  <FamilyName>Leung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Pulimood</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Neal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Robson</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>85</VolumeID>
                <FirstPage>1928</FirstPage>
                <LastPage>36</LastPage>
                <Occurrence Type="PID">
                  <Handle>11747336</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1054/bjoc.2001.2179</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XhsVWnu70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001;85:1928–36.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_3">
              <CitationNumber>97</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Tam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>McGlynn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Traynor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Mukherjee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Bartlett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Edwards</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>97</VolumeID>
                <FirstPage>378</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>17595657</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.bjc.6603871</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXotlSgtr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 2007;97:378–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_3">
              <CitationNumber>98</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HO</Initials>
                  <FamilyName>Duan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Kirley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SX</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WS</Initials>
                  <FamilyName>McDougal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Xiao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">TIP30 is associated with progression and metastasis of prostate cancer</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>123</VolumeID>
                <FirstPage>810</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>18528861</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.23638</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXovFWmtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhang H, Zhang Y, Duan HO, Kirley SD, Lin SX, McDougal WS, et al. TIP30 is associated with progression and metastasis of prostate cancer. Int J Cancer 2008;123:810–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_3">
              <CitationNumber>99</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Miyajima</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Maruyama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Bohgaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Shigemura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Shinohara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Nonomura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hatakeyama</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>3486</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>18451177</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-6059</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXltlSlt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Miyajima N, Maruyama S, Bohgaki M, Kano S, Shigemura M, Shinohara N, et al. TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. Cancer Res 2008;68:3486–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_3">
              <CitationNumber>100</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Dong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LH</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Revelo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>2315</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>16762975</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.2006-0048</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtVOht7vJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, et al. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 2006;20:2315–25.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
